Harbor MedTech’s Architect® Skin Substitute Awarded Medicare Coverage by First Coast Service Options, Inc.
Irvine, California – December 10, 2015. Harbor MedTech, Inc., a fully integrated and diversified tissue regeneration company, announced that it had received confirmation of a change from the Medicare Administrative Contractor, First Coast Service Options, Inc., to include coverage of the Company’s flagship product, Architect® when applied in the hospital outpatient and ambulatory surgery center settings.
First Coast Service Options, Inc., the Medicare Administrative Contractor for Florida, Puerto Rico and the U.S. Virgin Islands, modified its Local Coverage Determination (LCD) 36013 for treatment of diabetic foot ulcers (DFU and venous leg ulcers (VLU) to include Architect as an approved and reimbursable product. This is very important news as there are over 3.5 million Medicare patients in Florida alone.
With Architect now listed on the LCD, it is the only stabilized skin substitute for treating these difficult wounds representing a new class of skin substitutes engineered for a “One and Done” treatment option.
Architect is a unique acellular, extracellular collagen matrix (“ECM”) cleared by the FDA for use as a skin substitute to help manage the treatment of partial or full thickness skin wounds, including diabetic ulcers, venous ulcers, pressure ulcers/sores, trauma and surgical wounds. ECMs are commonly used as “skin substitutes” because of their important tissue regeneration properties. Unfortunately, most ECMs are susceptible to rapid degradation by the body’s natural inflammatory enzymes present in serious or chronic skin wounds. Architect on the other hand, is the only stabilized ECM, specifically engineered with Harbor’s patented BriDGE® technology to resist premature degradation and require only one application to the wound.
For more information about Harbor MedTech and Architect, please contact Customer Support:
Telephone: 949.679.4800 x200
Architect® and BriDGE® are registered trademarks of Harbor MedTech, Inc.